Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 12/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
| ▸ | POLD1 | P28340 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymidine_Triphosphate SCHEMBL18852394 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| Thymidine_Triphosphate SCHEMBL3502894 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| Thymidine_Triphosphate SCHEMBL17210989 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| Thymidine_Triphosphate SCHEMBL17211051 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| Thymidine_Triphosphate SCHEMBL625179 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| SCHEMBL3019703 | 0.98 | P2RY6 (0.70) | P2RY6P2RY2P2RY4 | |
| SCHEMBL3019709 | 0.98 | P2RY6 (0.70) | P2RY6P2RY2P2RY4 | |
| SCHEMBL17364583 | 0.98 | P2RY6 (0.70) | P2RY6P2RY2P2RY4 | |
| SCHEMBL8156931 | 0.94 | P2RY6 (0.66) | P2RY6P2RY2P2RY4 | |
| SCHEMBL21577343 | 0.92 | P2RY6 (0.63) | P2RY6P2RY2P2RY4POLBPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| US-20210340612-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | Omniome, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-10975427-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | Omniome, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20180208983-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | Omniome, Inc. (US) | 2018-07-26 | — | — | US | disclosed |
| US-8399196-B2 | Nucleic acid sequencing methods, kits and reagents | GENEFORM TECHNOLOGIES LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-20070148645-A1 | Nucleic acid sequencing methods, kits and reagents | GENEFORM TECHNOLOGIES LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208983-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | P2RY6 706/4885P2RY2 1576/4885P2RY4 625/4885 |
| US-20070148645-A1 | Nucleic acid sequencing methods, kits and reagents | UNG, DNTT, RNGTT | P2RY6 1915/4885P2RY2 3016/4885P2RY4 2195/4885 |
| US-10975427-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | RNGTT, POLRMT, POLM | P2RY6 706/4885P2RY2 1576/4885P2RY4 625/4885 |
| US-20210340612-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | P2RY6 706/4885P2RY2 1576/4885P2RY4 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.